News For JNJ From The Last 14 Days Check below for free stories on JNJ the last two weeks.
There are 15 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 10, 2012
|
| 07:10 EDT |  | JNJ |
| | 06:18 EDT | | JNJ |
|
|
February 9, 2012
|
| 16:27 EDT |  | JNJ |
| theflyonthewall.com: | Leerink's biotech and pharmaceuticals analysts hold a conference call | | Biotech Analysts Schimmer and Liang, along with Pharmaceuticals Analyst Fernandez, review the reimbursement process for drugs in France on an Analyst/Industry conference call. Relevant covered companies ACOR, AMGN, AMLN, AUXL, BIIB, BMY, GILD, HGSI, ITMN, JNJ, NVS, PFE and VRTX may be included on the Analyst/Industry conference call to be held on February 10 at 11 am. :theflyonthewall.com |
|
|
February 8, 2012
|
| 11:34 EDT |  | JNJ |
| theflyonthewall.com: | Watson reaches settlement with Janssen over generic Ortho Tri-Cyclen LO | | Watson Pharmaceuticals (WPI) announced earlier that its subsidiary, Watson Laboratories, has reached a settlement with Janssen Pharmaceuticals (JNJ) on outstanding patent litigation related to Watson's generic version of Janssen's Ortho Tri-Cyclen LO tablets. As part of the settlement, the parties have entered into a supply agreement whereby Janssen will manufacture and supply Watson with an authorized generic version of Ortho Tri-Cyclen LO. Watson will have the right to market and distribute the authorized generic on December 31, 2015, or earlier under certain circumstances. Other details of the settlement were not disclosed. :theflyonthewall.com |
|
|
February 7, 2012
|
| 10:33 EDT | | JNJ |
| theflyonthewall.com: | Argus Research's healthcare analyst holds a conference call | | Senior Healthcare Analyst Toung discusses healthcare and growth ideas for 2012 on an Analyst/Industry conference call. Relevant covered companies ABC, ABT, AET, BAX, BDX, BSX, CAH, CHSI, CI, ESRX, HMA, HOLX, HUM, IART, JNJ, MCK, MDT, MHS, STJ, SYK, UNH and ZMH may be included on the Analyst/Industry conference call to be held on February 8 at 11 am. :theflyonthewall.com |
|
|
February 3, 2012
|
| 12:30 EDT | | JNJ |
| theflyonthewall.com: | Johnson & Johnson sued in China over alleged price fixing, Shanghai Daily says |
 Subscribe for More Information :theflyonthewall.com |
|
|
February 2, 2012
|
| 14:15 EDT |  | JNJ |
| theflyonthewall.com: | da Vinci reimbursement set for April in Japan, says Collins Stewart | | Collins Stewart confirmed with Intuitive Surgical (ISRG) management that the Japanese Ministry of Health indicated da Vinci prostatectomy is scheduled to be reimbursed beginning in April. The firm expects Intuitive Surgical, along with its Japanese partner Johnson and Johnson (JNJ), to pursue reimbursement for additional procedures. Collins Stewart says it is now more confident in Intuitive Surgical's long-term growth story and keeps a Buy rating on the stock. Note Lazard Capital said this morning in a note to investors that Japan is moving towards complete da Vinci prostatectomy reimbursement. :theflyonthewall.com |
| | 14:05 EDT | | JNJ |
| theflyonthewall.com: | FDA and industry reach agreement in principle on medical device user fees | | The FDA and representatives from the medical device industry have reached an agreement in principle on proposed recommendations for the third reauthorization of a medical device user fee program. The recommendations would authorize the FDA to collect $595M in user fees over five years, plus adjustments for inflation. Details of the agreement, such as the fee structure, are expected to be finalized soon. :theflyonthewall.com |
| | 10:19 EDT |  | JNJ |
| theflyonthewall.com: | On The Fly: Analyst Downgrade Summary | | Today's noteworthy downgrades include: Autoliv (ALV) downgraded to Sell from Buy at Citigroup...JDSU (JDSU) downgraded to Neutral from Buy at UBS...Vanguard Health (VHS) downgraded to Market Perform from Outperform at Wells Fargo...Steel Dynamics (STLD) downgraded to Neutral from Buy at BofA/Merrill...AK Steel (AKS) downgraded to Underperform from Neutral at BofA/Merrill...Northrop Grumman (NOC) downgraded to Underperform from Neutral at BofA/Merrill...Sykes Enterprises (SYKE) downgraded to Neutral from Outperform at RW Baird...NYSE Euronext (NYX) downgraded to Market Perform from Outperform at BMO Capital...QuinStreet (QNST) downgraded to Hold from Buy at ThinkEquity...Edwards Lifesciences (EW) downgraded to Neutral from Outperform at Credit Suisse...Ann Inc. (ANN) downgraded to Underweight from Neutral at Piper Jaffray...Johnson & Johnson (JNJ) downgraded to Market Perform from Outperform at First Global. :theflyonthewall.com |
| | 09:40 EDT | | JNJ |
| theflyonthewall.com: | Johnson & Johnson downgraded to Market Perform from Outperform at First Global |
Subscribe for More Information :theflyonthewall.com |
| | 07:35 EDT | | JNJ |
| theflyonthewall.com: | U.K. agency says it can't justify pricey J&J cancer drug, Bloomberg reports | | In the U.K., Johnson & Johnson's (JNJ) prostate cancer medicine Zytig, discovered there and developed with funds from U.K. charities, is too expensive for the country’s National Health Service, reports Bloomberg. The National Institute for Health and Clinical Excellence said the NHS shouldn’t pay for the drug because its benefits don’t justify the cost even after J&J agreed to reduce the price. Reference Link :theflyonthewall.com |
|
|
February 1, 2012
|
| 08:00 EDT | | JNJ |
|
|
January 31, 2012
|
| 07:20 EDT | | JNJ |
| theflyonthewall.com: | J&J changes McNeil unit leadership, WSJ reports | | Johnson & Johnson (JNJ) is again shaking up its troubled McNeil Consumer Healthcare unit, replacing two company group chairmen, reports the Wall Street Journal. Reference Link :theflyonthewall.com |
| | 07:04 EDT |  | JNJ |
|
|
January 30, 2012
|
| 07:29 EDT | | JNJ |
| theflyonthewall.com: | The FDA Pediatric Advisory Committee to hold a meeting | | The Committee discusses pediatric-focused safety reviews, as mandated by Best Pharmaceuticals for Children Act and Pediatric Research Equity Act for Novartis Pharmaceuticals' Focalin XR, Shire's Daytrana, AstraZeneca's Seroquel and Atacand, Johnson & Johnson's Pancreaze, Eurand's Zenpep, Solvay Pharma's Creon, Meda Pharma's Xerese cream, Genentech's Xolair, Daiichi Sankyo's Benicar, Bayer's Mirena and Plan B One Step, and Boehringer Ingelheim's Flomax in a meeting to be held in Gaithersburg, Maryland on January 30 at 8 am. Webcast Link :theflyonthewall.com |
|
|
|
